A Study to Test for Genetic Changes that Affect Treatment in Patients With Non-Small Cell Lung Cancer

Your blood may contain certain genetic mutations that make it potentially more likely to respond to certain drugs.

Open to people ages 18 years and up

• No prior systemic treatment for unresectable stage IIIB or IV NSCLC
• Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb not amenable to treatment with combined modality chemoradiation (advanced) or Stage IV (metastatic) NSCLC
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
• Measurable disease
• Adequate recovery from most recent systemic or local treatment for cancer
• Adequate organ function
• Life expectancy greater than or equal to (>/=) 12 weeks
• For female participants of childbearing potential and male participants, willingness to use acceptable methods of contraception

• Inability to swallow oral medication
• Women who are pregnant or lactating
• Symptomatic, untreated CNS metastases
• History of malignancy other than NSLCL within 5 years prior to screening with the exception of malignancies with negligible risk of metastasis or death
• Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to randomization, unstable arrhythmias, or unstable angina
• Known human immunodeficiency virus (HIV) positivity or autoimmune deficiency syndrome (AIDS)-related illness
• Either a concurrent condition or history of a prior condition that places the patient at unacceptable risk if he/she were treated with the study drug or confounds the ability to interpret data from the study
• Inability to comply with other requirements of the protocol